Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate

Bibliography

• Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94
   PubMed Web of Science ®Google Scholar
• May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008;28:s5-10
   PubMed Web of Science ®Google Scholar
• Chammoro A. Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004;17:1-5
   Google Scholar
• Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004;61:498-511
   PubMed Web of Science ®Google Scholar
• Palomo I, Toro C, Alarcon M. The role of platelets in the pathophysiology of atherosclerosis. Mol Med Rep 2008;1:179-84
   PubMed Web of Science ®Google Scholar
• Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-72
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Parlak E, van Werkum JW, Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010;8:482-8
   PubMed Web of Science ®Google Scholar
• Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010;103:71-82
   PubMed Web of Science ®Google Scholar
• Evangelista V, Manarini S, Dell'Elba G, Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 2005;94:568-77
   PubMed Web of Science ®Google Scholar
• Xiao Z, Theroux P. Clopidogrel inhibits platelet–leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004;43:1982-8
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Bertrand ME, Berger PB, Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT III, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Darius H, Munzel T, Huber K, Clopidogrel salts – pharmacokinetic, pharmacodynamic and clinical aspects. J Kardiol 2009;16:412-16
   Google Scholar
• Sung-Doo K, Wonku K, Hae Won L, Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther 2009;31:793-800
   PubMedGoogle Scholar
• Neubauer H, Kruger JC, Lask S, Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 2009;98:533-40
   PubMedGoogle Scholar
• Tsoumani ME, Kalantzi KI, Dimitriou AA, Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome. Comparison with clopidogrel hydrogen sulfate. Angiology 2011; [Epub ahead of print]
   PubMedGoogle Scholar
• Mitsios JV, Papathanasiou AI, Rodis FI, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8
   PubMed Web of Science ®Google Scholar
• Kalantzi KI, Dimitriou AA, Milionis HJ, Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes. J Thromb Haemost 2011;4:875-8
   Google Scholar
• Kalantzi KI, Dimitriou AA, Goudevenos JA, Tselepis AD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within one month of treatment. Platelets 2011; [Epub ahead of print]
   PubMedGoogle Scholar
• Bonello L, Camoin-Jau L, Arques S, Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Karabina S-A, Tambaki AP, Altered distribution of platelet activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002;43:256-63
   PubMed Web of Science ®Google Scholar
• Garber MC, Nau DP, Erickson SR, The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004;42:649-52
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 2007;195:e217-23
   PubMedGoogle Scholar
• Cesari F, Marcucci R, Caporale R. Relationship between high platelet turnover and platelet function in high- risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008;99:930-5
   PubMed Web of Science ®Google Scholar
• Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl 2008;10(Suppl A):A28-34
   Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO, Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302
   PubMed Web of Science ®Google Scholar
• Schumacher WA, Bostwick JS, Ogletree ML, Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats. J Pharmacol Exp Ther 2007;322:369-77
   PubMedGoogle Scholar
• Cuisset T, Frere C, Quilici J, Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48:1339-45
   PubMed Web of Science ®Google Scholar
• Palmerini T, Barozzi C, Tomasi L, A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res 2010;125:309-14
   PubMedGoogle Scholar
• Aleil B, Jacquemin L, De Poli F, Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008;1:631-8
   PubMedGoogle Scholar
• von Beckerath N, Kastrati A, Wieczorek A, A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814-19
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;24:2312-17
   Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42
   PubMed Web of Science ®Google Scholar
• Gawaz M, Langer H, May EA. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-83
   PubMed Web of Science ®Google Scholar
• Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005;96:612-16
   PubMed Web of Science ®Google Scholar
• Gawaz M. Do platelets trigger atherosclerosis? Thromb Haemost 2003;90:971-2
   PubMed Web of Science ®Google Scholar
• Gawaz M, Brand K, Dickfeld T, Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000;148:75-85
   PubMed Web of Science ®Google Scholar
• Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009;102:248-57
   PubMed Web of Science ®Google Scholar
• von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007;100:27-40
   PubMed Web of Science ®Google Scholar
• Ott I, Neumann FJ, Gawaz M, Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996;94:1239-46
   PubMed Web of Science ®Google Scholar
• Sarma J, Laan CA, Alam S, Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-71
   PubMed Web of Science ®Google Scholar
• Smith SMG, Judge HM, Peters G, Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004;15:465-74
   PubMed Web of Science ®Google Scholar
• Neubauer H, Gunesdogan B, Hanefeld C, Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function. A flow cytometry study. Eur Heart J 2003;24:1744-9
   PubMed Web of Science ®Google Scholar
• Saw J, Brennan DM, Steinhubl SR, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-5
   PubMed Web of Science ®Google Scholar
• Fernando H, Dart AM, Peter K, Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. J Thromb Haemost 2011;105:933-1123
   Google Scholar